Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.290
+0.110 (9.32%)
Nov 4, 2024, 4:00 PM EST - Market closed
Spero Therapeutics Employees
Spero Therapeutics had 46 employees as of December 31, 2023. The number of employees increased by 11 or 31.43% compared to the previous year.
Employees
46
Change (1Y)
11
Growth (1Y)
31.43%
Revenue / Employee
$2,575,196
Profits / Employee
$379,457
Market Cap
69.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
LENSAR | 130 |
Precision BioSciences | 109 |
Connect Biopharma Holdings | 81 |
InspireMD | 66 |
Forian | 37 |
Citius Pharmaceuticals | 22 |
Entera Bio | 18 |
SPRO News
- 19 days ago - Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - GlobeNewsWire
- 4 weeks ago - Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - GlobeNewsWire
- 3 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 - GlobeNewsWire
- 4 months ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - GlobeNewsWire
- 6 months ago - Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update - GlobeNewsWire